Author: Zacks

Home » Archives for Zacks
Zacks Investment Research
Post

When in Doubt, Zoom Out; Bear Markets Are a Goldmine

It’s been a battlefield within the market landscape throughout 2022, with high-growth and tech stocks seemingly walking around with big targets on their backs. Buyers have entirely retreated, and bears have been pushing forward all year. It’s been exhausting, and bears keep reloading. Day-traders and scalpers undoubtedly welcome the volatility, but the same can’t be...

Zacks Investment Research
Post

Have Earnings Estimates Come Down Enough?

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points:   For 2022 Q2, total S&P 500 earnings are expected to increase +2.5% from the same period last...

Zacks Investment Research
Post

Have Earnings Estimates Come Down Enough?

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points:   For 2022 Q2, total S&P 500 earnings are expected to increase +2.5% from the same period last...

Zacks Investment Research
Post

Bull of the Day: J.Jill (JILL)

J.Jill, Inc. JILL is benefiting from the economic reopening as women are returning to “experiences” in 2022. This Zacks Rank #1 (Strong Buy) is expected to grow earnings by double digits this year. J.Jill is a national women’s apparel retailer. It has 249 stores nationwide and sells online through its ecommerce platform. It’s a small...

Zacks Investment Research
Post

3 Bets on an Ecommerce Industry That Remains in the Doldrums

About The Industry Internet – Commerce continues to evolve as the technologies driving it advance. On the one side are increasingly powerful and capable user devices. On the other are sophisticated, AI-enabled software platforms facilitating transactions that are thereby, more capable of delivering user satisfaction. Social commerce and chatbots are further facilitating things. Differentiation comes...

Zacks Investment Research
Post

Bull of the Day: Dollar Tree, Inc. (DLTR)

Consumer sentiment is tumbling as people stare at sky-high gas prices and grocery bills. Inflation remains at 40-year highs and many consumers are already cutting back on major expenses and looking for savings anywhere they can. Discount retail standout Dollar Tree, Inc. DLTR has grown during an array of economic environments and it’s poised to...

Zacks Investment Research
Post

Tenet Healthcare (THC) Unit Ties Up to Boost Urology Services

Tenet Healthcare Corporation’s THC subsidiary, United Surgical Partners International (“USPI”), recently inked a definitive deal with the well-established urology affiliate practices network of the United States – United Urology Group (“UUG”). The deal revolves around creating a joint venture partnership, through which the largest U.S. ambulatory platform — USPI — will purchase part of UUG’s...

Zacks Investment Research
Post

Will Earnings Estimates Finally Come Down?

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points:   For 2022 Q2, total S&P 500 earnings are expected to increase +2.1% from the same period last...

Zacks Investment Research
Post

Will Earnings Estimates Finally Come Down?

Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>> Here are the key points:   For 2022 Q2, total S&P 500 earnings are expected to increase +2.1% from the same period last...

Zacks Investment Research
Post

Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

Exelixis, Inc. EXEL announced that it has initiated the phase III STELLAR-303 study that is evaluating its next-generation tyrosine kinase inhibitor, XL092, in combination with atezolizumab for treating patients with metastatic colorectal cancer (“CRC”). The STELLAR-303 study will investigate the combo of XL092 + atezolizumab versus Stivarga (regorafenib) for treating patients with metastatic CRC (which...